News & Updates

Show Multimedia Only

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

19 Aug 2025 by

The use of lenacapavir is highly efficacious in pregnant and lactating people (PLP), with zero participants acquiring HIV, as shown by the results of the PURPOSE 1 study.

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

19 Aug 2025

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

Tofacitinib shows promise in TNFi-resistant Blau syndrome

19 Aug 2025

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025 by

Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.

Combo therapy enhances fat loss while preserving lean mass

19 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025 by

New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

18 Aug 2025

Personalized approach may improve PrEP uptake in MSM, transgenders

18 Aug 2025 by

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

Personalized approach may improve PrEP uptake in MSM, transgenders

18 Aug 2025

Retinal fluid may persist even long after anti-VEGF Tx for nAMD

18 Aug 2025 by

A systematic review and meta-analysis show persistence of retinal fluid (RF) up to 2 years after anti-VEGF treatment for neovascular age-related macular degeneration (nAMD).

Retinal fluid may persist even long after anti-VEGF Tx for nAMD

18 Aug 2025

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Hormone therapy use has no bearing on severe COVID-19 outcomes

17 Aug 2025

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

Combined treatment with dapagliflozin and spironolactone results in greater reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) than dapagliflozine alone in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Dapagliflozin plus spironolactone improves outcomes in HFpEF

17 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Tofacitinib shows promise in TNFi-resistant Blau syndrome

Combo therapy enhances fat loss while preserving lean mass

Combo therapy enhances fat loss while preserving lean mass

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

GLP-1RA, DPP-4i do not prevent COVID-19 but reduce hospitalization risk in infected patients

Personalized approach may improve PrEP uptake in MSM, transgenders

Personalized approach may improve PrEP uptake in MSM, transgenders

Retinal fluid may persist even long after anti-VEGF Tx for nAMD

Retinal fluid may persist even long after anti-VEGF Tx for nAMD

Hormone therapy use has no bearing on severe COVID-19 outcomes

Hormone therapy use has no bearing on severe COVID-19 outcomes

Dapagliflozin plus spironolactone improves outcomes in HFpEF

Dapagliflozin plus spironolactone improves outcomes in HFpEF